Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of...
Source : https://pubmed.ncbi.nlm.nih.gov/34073318/
Non-small cell lung cancer (NSCLC) patients harboring a KRAS mutation have unfavorable therapeutic outcomes with chemotherapies, and the mutation also renders tolerance to immunotherapies. There is an unmet need for...
Source : https://pubmed.ncbi.nlm.nih.gov/34065402/
Lung carcinoma is still the most common malignancy worldwide. One of the major subtypes of non-small cell lung cancer (NSCLC) is adenocarcinoma (AC). As driver mutations and hence therapies differ...
Click on the icon above to preview and download our full comprehensive coverage from Day 2 at the 2021 ASCO Virtual Conference
Click on the icon above to preview and download our full comprehensive coverage from Day 2 at the 2021 ASCO Virtual Conference